Navigation Links
Questcor Reports First Quarter Financial Results

ANAHEIM, Calif., April 30, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the first quarter ended March 31, 2013. Financial results include BioVectra Inc. since January 18, 2013.Three Months Ended 03/31/13Three Months Ended 03/31/12

 Percentage ChangeNet Sales

$135.1 Million

$96.0 Million

41%GAAP Diluted EPS



12%Non-GAAP Diluted EPS



25%Net sales for the first quarter of 2013 were $135.1 million, with BioVectra contributing $8.4 million. Year-over-year net sales grew 41 percent from $96.0 million in the first quarter of 2012. Net sales growth was driven by the expanded usage of H.P. Acthar® Gel (repository corticotropin injection) by nephrologists in the treatment of nephrotic syndrome (NS) and by rheumatologists in the treatment of dermatomyositis, polymyositis, systemic lupus erythematosus, and rheumatoid arthritis, as well as continued prescribing by neurologists in the treatment of multiple sclerosis (MS) exacerbations and infantile spasms (IS).

Net sales in the first quarter of 2013 were negatively impacted by the effects of several transitional events, including: distribution channel disruptions associated with implementing the Medicaid rebate change, the timing of Acthar orders that were received and filled at the end of fourth quarter 2012 and the introduction of a new reimbursement support center. This was partially offset by the positive impact of a lower Medicaid rebate rate and the acquisition of BioVectra. Based on its analysis of prescription trends, Questcor believes that the decline in its net sales from the fourth quarter of 2012 to the first quarter of 2013 reflected these transitional issues, as well as a reduction in the number of prescriptions of Acthar to treat MS exacerbations. The Company believes that insurance coverage for Acthar continues to remain favorable, when Acthar is prescribed for on-label indications for patients in need of an additional FDA-approved treatment alternative.

Questcor shipped 4,830 vials of Acthar during the first quarter of 2013 compared to 4,111 vials in the first quarter of 2012 and 6,330 vials in the fourth quarter of 2012. The Company shipped 2,550 vials of Acthar to its distributor in April 2013, which is a record number of vials shipped in a single month.  The Company believes this strong demand primarily reflects the transitional nature of the factors that negatively impacted first quarter net sales. As the Company has previously disclosed, monthly and quarterly vial shipments are subject to significant variation due to the size and timing of individual orders received from Questcor's distributor. The timing of when these orders are received and filled can significantly affect net sales and net income in any particular quarter. For example, in late December 2012, Questcor received and shipped two orders that represented 360 vials of Acthar. The Company believes that investors should consider the Company's results over several quarters when analyzing the Company's performance.

GAAP earnings for the first quarter of 2013 were $0.65 per diluted common share, compared to $0.58 per diluted common share for last year's comparable quarter. Non-GAAP earnings for the quarter ended March 31, 2013 were $0.76 per diluted common share and exclude non-cash share-based compensation expense, impairment of purchased technology, foreign currency transaction losses, interest expense related to our contingent consideration in conjunction with our acquisition of BioVectra, non-cash compensation expense and depreciation and amortization expense. Non-GAAP earnings for the year ago quarter were $0.61 per diluted common share. The reconciliation between GAAP and Non-GAAP financial measures are provided with the financial tables included with this release.

"Our first quarter results were below our expectations," said Don M. Bailey, President and CEO of Questcor. "However, vial shipment activity and prescription levels in MS and rheumatology in late March and throughout April appear to indicate that positive sales momentum has returned. In particular, we note that our newest initiative related to the promotion of Acthar for dematomyositis and polymyositis is off to a strong start."

Mr. Bailey continued, "In the first quarter, we made several operational changes aimed at ensuring and improving the delivery of Acthar for patients who rely on this important drug. We continue to seek to improve our business operations in order to benefit both Acthar patients and our shareholders by establishing a solid foundation for potential additional growth."

"Total new paid prescriptions for Acthar were approximately 1,725 to 1,750 in the first quarter, an increase of about 16% year-over-year and a decrease of about 9% sequentially," commented Steve Cartt, Chief Operating Officer of Questcor. "New paid prescriptions for NS, which represent about half of our Acthar business, were about 385-395 in the quarter, up about 56% year-over-year and up about 5% over the fourth quarter of 2012. New paid prescriptions for MS, which represent about a quarter of our Acthar business, were about 1,015 to 1,025, roughly flat year-over-year and down 17% from the prior quarter. New paid prescriptions for IS were 155 to 165. Net sales related to IS were positively influenced by the reduction of the Medicaid rebate in the quarter. New paid prescriptions for the on-label rheumatology indications were 140-150, up about 58% sequentially."

Mr. Cartt continued, "Consistent with the level of our vial sales in April, new paid prescription activity in April has been robust. While the second quarter is only about one-third complete, NS continues to grow, MS is on track to recover from first quarter softness, and rheumatology may well be up sharply from the first quarter."

To allow comparable analysis, the company has defined new paid prescriptions in the above paragraphs to include prescriptions covered by commercial carriers, Medicare, Medicaid and Tricare in all periods regardless of the rebate percentage applicable in those periods. The numbers do not include prescriptions filled through the Acthar free drug program.

Research and Development ProgramsQuestcor's continued strong financial performance has enabled the Company to increase investment in research programs to further clarify the potential immune-modulating properties of Acthar and identify Acthar mechanisms of action applicable to other inflammatory and auto-immune diseases with high unmet medical need. The Company is also in the process of identifying new patient populations in which to evaluate Acthar through clinical studies.  Additionally, Questcor has funded or has approved funding for approximately 70 other research projects, including company-sponsored clinical and pre-clinical studies and independent physician sponsored studies.

Label Enhancement Strategy:

  • Amyotrophic Lateral Sclerosis (ALS): Questcor has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Phase 2 clinical trial of Acthar for the treatment of amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease. ALS is a life-threatening, progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The Company expects to initiate the Phase 2 study in the second quarter of 2013 and has submitted a request for Orphan Designation to FDA.
  • Diabetic Nephropathy: Enrollment continues in a company-sponsored Phase 2 IND trial to evaluate the efficacy and safety of Acthar in patients with diabetic nephropathy, one of the most common causes of end-stage renal disease in the United States.
  • Research Regarding Approved Indications:

  • Idiopathic Membranous Nephropathy: Enrollment continues in a company-sponsored Phase 4 trial in idiopathic membranous nephropathy. Patients enrolled in this study are refractory, or non-responsive, to current standard therapies or have relapsed after partial remission on current standard therapies.
  • Lupus: Enrollment is underway in a company-sponsored multi-site Phase 4 company-sponsored clinical trial to evaluate the efficacy and safety of daily Acthar administration over a 6-month period in patients with persistently active lupus.
  • Lupus Exacerbations:  Questcor is providing grant support for a prospective independent investigator initiated study evaluating Acthar in the treatment of lupus exacerbations.  The Company has recently been informed by the investigator that enrollment for this study has been completed and that the study should be completed by the end of the second quarter.
  • Cash, Share Repurchase Program and DividendsAs of April 19, 2013, Questcor's cash, cash equivalents and short-term investments totaled $156.3 million. There were no share repurchases during the first quarter of 2013 and Questcor had 6.3 million remaining authorized shares under its common stock repurchase plan. Shares outstanding at March 31, 2013, were 59.6 million shares, a decrease of 3.5 million shares from March 31, 2012.

    The Company issued its second quarter cash dividend of $0.25 per share to all shareholders of record at the close of business on April 22, 2013. The dividend is scheduled to be paid on or about April 30, 2013. Questcor currently intends to pay regular quarterly cash dividends for the foreseeable future.

    Acthar Label InformationThe product label for Acthar includes 19 FDA-approved indications. Substantially all of the Company's net sales currently result from Acthar prescriptions for the following on-label indications of:

  • Nephrotic Syndrome (NS): "to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." NS can result from several underlying conditions, and prescribing physicians indicate that Acthar is most commonly being prescribed for patients who suffer from NS due to idiopathic membranous nephropathy, focal segmental glomerulosclerosis (FSGS), IgA nephropathy, minimal change disease and lupus nephritis.
  • Multiple Sclerosis (MS): "for the treatment of acute exacerbations of multiple sclerosis in adults. Clinical controlled trials have shown H.P. Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease." When Acthar is used, it is typically prescribed as second line treatment for patients with MS exacerbations.
  • Infantile Spasms (IS): "as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age."
  • Collagen Diseases: "during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis)."
  • Rheumatic Disorders: "as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis, Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis."
  • Non-GAAP Financial Measures The Company believes it is important to share non-GAAP financial measures with shareholders as these measures may better represent the ongoing economics of the business and reflect how we manage the business. Accordingly, management believes investors' understanding of the Company's financial performance is enhanced as a result of the disclosure of these non-GAAP financial measures. Non-GAAP financial measures should not be viewed in isolation, or as a substitute for, or as superior to, reported GAAP financial measures. The reconciliation between GAAP and Non-GAAP financial measures are provided with the financial tables included with this release.

    Conference Call and Webcast Details The Company will host a conference call and slide presentation via webcast today, April 30, 2013, at 4:30 p.m. ET/ 1:30 p.m. PT. The call can be accessed three ways:

  • By webcast: At Questcor's investor relations website,
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. is (877) 354-0215. For participants outside the U.S., the dial-in number is (253) 237-1173.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call. The telephone dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is 34200996.
  • About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit  

    Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "ensuring," "estimates," "expects," "growth," "may," "momentum," "plans," "potential," "remain," "should," "start," "substantial," "sustainable" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Our reliance on Acthar for substantially all of our net sales and profits;
  • Reductions in vials used per prescription resulting from changes in treatment regimens by physicians or patient compliance with physician recommendations;
  • Our ability to receive high reimbursement levels from third party payers;
  • The complex nature of our manufacturing process and the potential for supply disruptions or other business disruptions;
  • The lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products;
  • Our ability to continue to generate revenue from sales of Acthar to treat on-label indications associated with NS, MS, IS or rheumatology-related conditions, and our ability to develop other therapeutic uses for Acthar;
  • Research and development risks, including risks associated with Questcor's work in the area of NS and Lupus, our reliance on third-parties to conduct research and development, and the ability of research and development to generate successful results;
  • The results of any pending or future litigation, investigations or claims, including with respect to the investigation by the United States Attorney's Office for the Eastern District of Pennsylvania regarding the Company's promotional practices and litigation brought by certain shareholders arising from the federal securities laws, currently pending in the United States District Court for the Central District of California;
  • Our ability to comply with federal and state regulations, including regulations relating to pharmaceutical sales and marketing practices;
  • Regulatory changes or other policy actions by governmental authorities and other third parties in connection with U.S. health care reform or efforts to reduce federal and state government deficits;
  • An increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government entities;
  • Our ability to estimate reserves required for Acthar used by government entities and Medicaid-eligible patients and the impact that unforeseen invoicing of historical Medicaid prescriptions may have upon our results;
  • Our ability to effectively manage our growth, including the expansion of our sales forces, and our reliance on key personnel;
  • Our ability to integrate the BioVectra business with our business and to manage, and grow, a contract manufacturing business;
  • Our ability to comply with foreign regulations related to the operation of BioVectra's business;
  • The impact to our business caused by economic conditions;
  • Our ability to protect our proprietary rights;
  • The risk of product liability lawsuits;
  • Unforeseen business interruptions and security breaches;
  • Volatility in Questcor's monthly and quarterly Acthar shipments, estimated channel inventory, and end-user demand, as well as volatility in our stock price;
  • Our ability and willingness to continue to pay our quarterly dividend or make future increases in our quarterly dividend; and
  • Other risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission, or SEC, on February 27, 2013, and other documents filed with the SEC.
  • The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

    Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date of this release.

    For more information, please visit or


    (unaudited)Three Months EndedMarch 31,20132012RevenuePharmaceutical net sales



    95,968Contract manufacturing net sales

    8,358—Total net sales

    135,12995,968Cost of sales (exclusive of amortization of purchased technology)

    16,1895,520Gross profit

    118,94090,448Operating expenses:Selling and marketing

    35,46121,716General and administrative

    12,5485,442Research and development

    10,7935,665Depreciation and amortization

    1,070290Impairment of purchased technology

    719—Total operating expenses

    60,59133,113Income from operations

    58,34957,335Interest and other (expense) income, net

    (342)216Foreign currency transaction loss

    (488)—Income before income taxes

    57,51957,551Income tax expense

    18,45519,008Net income



    38,543Change in unrealized gains or losses on available-for-sale securities, net of related tax effects and changes in foreign currency translation adjustments.

    (1,194)91Comprehensive income



    38,634Net income per share:Basic






    0.58Shares used in computing net income per share:Basic


    60,27166,471Dividends declared per share of common stock



    — Reconciliation of Non-GAAP Adjusted FinancialThree Months EndedMarch 31,20132012Adjusted net income


    40,610Share-based compensation expense (1)


    (1,550)Depreciation and amortization expense (2)


    (196)Interest expense associated with contingent consideration (3)


    0Compensation expense associated with BV Trust (4)


    0Foreign currency transaction loss (5)


    0Tax adjustments (6)


    (321)Impairment of purchased technology (7)


    -Net income - GAAP


    38,543Adjusted net income per share - basic


    .64Share-based compensation expense (1)


    (0.02)Depreciation and amortization expense (2)


    (0.00)Interest expense associated with contingent consideration (3)


    —Compensation expense associated with BV Trust (4)


    —Foreign currency transaction loss (5)


    —Tax adjustments (6)

    (0.01)Impairment of purchased technology (7)


    —Net income per share - basic


    .61Adjusted net income per share - diluted


    .61Share-based compensation expense (1)


    (0.02)Depreciation and amortization expense (2)


    (0.00)Interest expense associated with contingent consideration (3)


    —Compensation expense associated with BV Trust (4)


    —Foreign currency transaction loss (5)


    —Tax adjustments (6)

    (0.00)Impairment of purchased technology (7)


    —Net income per share - diluted


    .58Net sales - Questcor


    95,968Net sales - BioVectra


    —Consolidated net sales


    95,968Net income per share – basic and diluted may not foot due to rounding. Use of Non-GAAP Financial Measures Our "non-GAAP adjusted net income" excludes the following items from GAAP net income: 1. Share-based compensation expense.2. Depreciation and amortization expense, including amortization expense on our purchased intangibles.3. Interest expense associated with the net present value adjustment on our contingent consideration.4.  Compensation expense associated with the BV Trust agreement.5.  Foreign currency transaction loss.6.  Tax adjustment primarily relate to write-off of 1997-2000 Federal R&D tax credits.7.  Impairment of purchased technology related to our acquisition of Doral. QUESTCOR PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except share information)

    (unaudited)March 31,
    2013December 31,
    2012ASSETSCurrent assets:Cash and cash equivalents



    80,608Short-term investments

    78,02074,705Total cash, cash equivalents and short-term investments

    153,424155,313Accounts receivable, net of allowances for doubtful accounts of $379 and $0 at March 31, 2013 and December 31, 2012, respectively

    59,27861,417Inventories, net of allowances of $1,205 and $52 at March 31, 2013 and December 31, 2012, respectively

    16,7869,909Prepaid expenses and other current assets

    6,4854,900Deferred tax assets

    5,4645,737Total current assets

    241,437237,276Property and equipment, net

    35,7422,073Purchased technology, net


    20,597—Intangibles, net

    33,992—Deposits and other assets

    1,76670Deferred tax assets

    11,51911,519Total assets



    252,431LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable



    13,069Accrued compensation

    6,08921,300Sales-related reserves

    25,83037,376Dividend payable

    14,751—Current portion of contingent consideration

    4,485—Income taxes payable

    13,0037,360Current portion of long-term debt

    1,680—Other accrued liabilities

    13,82711,294Total current liabilities

    94,29590,399Long-term debt, less current portion

    16,062—Contingent consideration

    25,747—Non current deferred tax liability

    11,736—Other non current liabilities

    2,211203Total liabilities

    150,05190,602Shareholders' equity:Preferred stock, no par value, 5,334,285 shares authorized; none outstanding

    ——Common stock, no par value, 105,000,000 shares authorized, 59,554,198 and 58,544,206 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively

    26,69215,938Retained earnings

    170,164145,851Accumulated other comprehensive (loss) income

    (1,154)40Total shareholders' equity

    195,702161,829Total liabilities and shareholders' equity




    (unaudited)Three Months EndedMarch 31,20132012OPERATING ACTIVITIESNet income



    38,543Adjustments to reconcile net income to net cash provided by operating activities:Share-based compensation expense

    6,1482,296Deferred income taxes

    41167Amortization of investments

    182546Depreciation and amortization

    2,137290Impairment of purchased technology and goodwill

    719—Loss on disposal of property and equipment

    21—Changes in operating assets and liabilities, net of business acquisition:Accounts receivable


    4,637(298)Prepaid income taxes

    —760Prepaid expenses and other current assets

    (198)(272)Accounts payable

    (384)1,985Accrued compensation

    (15,211)(6,519)Sales-related reserves

    (11,546)(354)Income taxes payable

    5,64317,556Contingent consideration

    505—Other accrued liabilities

    538(13)Other non-current liabilities

    68(120)Net cash flows provided by operating activities

    41,45240,910INVESTING ACTIVITIESPurchase of property and equipment

    (562)(302)Purchase of short-term investments

    (33,539)(71,074)Proceeds from maturities of short-term investments

    30,03832,235Acquisition of BioVectra, net of cash received

    (46,692)—Deposits and other assets

    —4Net cash flows used in investing activities

    (50,755)(39,137)FINANCING ACTIVITIESRepayment of funded long-term debt

    (304)—Repayment of other long-term debt

    (119)—Income tax benefit realized from share-based compensation plans

    1,9911,380Issuance of common stock, net

    2,615956Repurchase of common stock

    —(28,987)Net cash flows provided by / (used in) financing activities

    4,183(26,651)Effect of cash on changes in exchange rates

    (84)—Decrease in cash and cash equivalents(5,204)(24,878)Cash and cash equivalents at beginning of period

    80,60888,469Cash and cash equivalents at end of period$


    63,591Supplemental Disclosures of Cash Flow Information:Cash paid for interest



    7Cash paid for income taxes



    32Supplemental Disclosures of Investing and Financing Activities:Dividend payable



    —In conjunction with the acquisition of BioVectra at January 18, 2013:Incremental fair value of assets acquired, net


    80,698Less: fair value of contingent consideration

    (30,383)50,315Loss on foreign exchange rate

    488Total cash paid for acquisition of BioVectra



    SOURCE Questcor Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Questcor to Report First Quarter Results on April 30, 2013
    2. Questcor Reports Fourth Quarter and Full Year 2012 Results
    3. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
    4. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
    5. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
    6. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
    7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
    8. Questcor Comments on Insurance Policy Bulletin
    9. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
    10. Questcor Pharmaceuticals to Present at Investor Conferences in September
    11. Questcor Reports Second Quarter Financial Results
    Post Your Comments:
    (Date:1/24/2020)... NEW YORK (PRWEB) , ... January 24, 2020 , ... ... the U.S. to implement a systematic reform of the health care system. Recently, practicing ... Doherty, Senior Vice President of Governmental Affairs and Public Policy at ACP, teamed with ...
    (Date:1/23/2020)... , ... January 23, 2020 , ... ... have trusted Australian Dream® for effective relief. Now, the company is ... , Australian Dream sought to develop a new design that better communicates the ...
    (Date:1/23/2020)... ... January 23, 2020 , ... ... holds true for the complex architecture providing function to a person’s hand, wrist, ... – not just an orthopedic surgeon -- when anything goes wrong up or ...
    Breaking Medicine Technology:
    (Date:1/27/2020)... ... January 27, 2020 , ... Controlled Contamination Services is ... the East/Central Regions. As Vice President of the East/Central Regions, she will be responsible ... has been with CCS since 2015 and has been an integral part of the ...
    (Date:1/27/2020)... ... 2020 , ... ResMed Launches AirFit F30i, Its First Tube-up Full Face CPAP ... launch of the AirFit F30i, Its First Tube-up Full Face ResMed CPAP Mask. The ... tube-down connection, compact under-the-nose or traditional over-the-nose cushion styles, and even memory foam versus ...
    (Date:1/24/2020)... ... January 24, 2020 , ... A new study ... Bellefonte Hospital (OLBH) achieved a 59 percent decrease in hospital onset CDI. This ... Disease Control and Prevention. , The retrospective pre-post [study recently published ...
    (Date:1/24/2020)... (PRWEB) , ... January 24, 2020 , ... ... teaming up with celebrity fitness expert and best-selling nutrition author Jorge Cruise to ... and intermittent fasting. , “I’m an enthusiastic advocate of intermittent fasting, that is ...
    (Date:1/23/2020)... ... January 23, 2020 , ... A January 7 article ... rid of them. The article quotes the president of the American Society of Plastic ... They can be caused by a person’s facial structure including an undefined jawline, a ...
    Breaking Medicine News(10 mins):